Edwards Lifesciences Corporation

EW

US28176E1082

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 18:04:50 16/07/2024 BST			5-day change	1st Jan Change
87.54 ^USD	-2.20%		-6.26%	+14.92%

01:07pm	Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating	MT
07-15	Sector Update: Health Care Stocks Edge Lower Late Afternoon	MT

Edwards Lifesciences Corporation Provides Sales Guidance for the Year 2018

January 08, 2018 at 04:00 pm

Edwards Lifesciences Corporation provided sales guidance for the year 2018. The company is projecting underlying sales growth in the 9% to 10% range.

Latest news about Edwards Lifesciences Corporation

Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating	12:07pm	MT
Sector Update: Health Care Stocks Edge Lower Late Afternoon	07-15	MT
Sector Update: Health Care Stocks Retreat Monday Afternoon	07-15	MT
Sector Update: Health	07-15	MT
Top Midday Stories: Trump Media & Technology Group Shares Rise After Ex-President Trump Survives Assassination Attempt; Goldman Sachs, BlackRock Q2 Earnings Gain; Edwards Lifesciences to Acquire Innovalve Bio Medical	07-15	MT
Edwards Lifesciences to Acquire Innovalve Bio Medical	07-15	MT
Jefferies Adjusts Price Target on Edwards Lifesciences to $105 From $102	07-15	MT
Edwards Lifesciences to Buy Innovalve for $300 Million	07-15	DJ
Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.	07-14	CI
Edwards Lifesciences Secures Health Canada's Approval for PASCAL Precision Transcatheter Valve Repair System	07-12	MT
Affluent Medical, Edwards Lifesciences Sign EUR15 Million Deals for Mitral Valve Technology	07-12	MT
Affluent: share price rises following agreement with Edwards	07-12	CF
Affluent Medical SA announced that it expects to receive ?15 million in funding from Edwards Lifesciences Corporation	07-11	CI
Edwards Lifesciences Corporation Appoints David T. Feinberg to the Board of Directors and as a Member of the Audit Committee of the Board	07-10	CI
Citigroup Adjusts Price Target on Edwards Lifesciences to $106 From $105	07-10	MT
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating	07-02	MT
Edwards Lifesciences Corporation(NYSE:EW) added to Russell Top 200 Value Index	06-30	CI
Edwards Lifesciences Corporation(NYSE:EW) added to Russell 3000E Value Index	06-30	CI
Edwards Lifesciences Corporation(NYSE:EW) added to Russell 3000 Value Index	06-30	CI
Edwards Lifesciences Corporation(NYSE:EW) added to Russell 1000 Value-Defensive Index	06-30	CI
Edwards Lifesciences Corporation(NYSE:EW) added to Russell 1000 Value Index	06-30	CI
Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing	06-20	MT
Edwards Lifesciences Corporation Announces Executive Changes	06-17	CI
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75	06-17	MT
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus	06-05	CI

Chart Edwards Lifesciences Corporation

Duration

Period

More charts

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).

Sector

Advanced Medical Equipment & Technology

Calendar

24/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Edwards Lifesciences Corporation: The story continues

April 23, 2024 at 04:25 pm

More Strategies

Ratings for Edwards Lifesciences Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

89.5 USD

Average target price

96.28 USD

Spread / Average Target

+7.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
EDWARDS LIFESCIENCES CORPORATION	+14.92%	53.93B
THERMO FISHER SCIENTIFIC	+4.14%	208B
DANAHER CORPORATION	+8.31%	182B
INTUITIVE SURGICAL, INC.	+29.17%	155B
BOSTON SCIENTIFIC CORPORATION	+35.06%	115B
SIEMENS HEALTHINEERS AG	+2.55%	66.52B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.47%	46.26B
AGILENT TECHNOLOGIES, INC.	-2.92%	38.22B
GE HEALTHCARE TECHNOLOGIES INC.	+6.49%	36.6B
RESMED, INC.	+19.88%	30.16B

Other Advanced Medical Equipment & Technology